Vor Bio raises $55.6 million through private placement to support clinical development.

From GlobeNewswire: 2024-12-27 09:00:15

Vor Bio has secured approximately $55.6 million in gross proceeds through a private investment in public equity financing, to extend its cash runway. The financing will result in the issuance of over 55 million shares of common stock and accompanying warrants. New investor Reid Hoffman and existing investor RA Capital Management led the financing, with each being granted a board seat. The company plans to use the funds to support clinical and preclinical development of its pipeline candidates. Vor Bio intends to announce updated clinical data from its Phase 1/2 VBP301 trial in the first half of 2025 and from the Phase 1/2a VBP101 trial in the second half of 2025.



Read more at GlobeNewswire: Vor Bio Announces $55.6 Million Private Placement